PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression

• Published in: Experimental biology and medicine (Maywood, N.J.) N.J.), 2022-09, Vol.247 (17), p.1518-1528
• Main Authors: Zhang, Nan, Liu, Si, Xu, Junxuan, Ning, Tingting, Xie, Sian, Min, Li, Zhu, Shengquan, Zhang, Shutian, Zhu, Shengtao
• Format: Article
• Language: English
• Subjects: beta Catenin - metabolism; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Neoplasms - pathology; Gene Expression Regulation, Neoplastic; Hexosamines - metabolism; Humans; Original Research; Phosphoglucomutase - metabolism; Wnt Signaling Pathway
• ISSN: 1535-3702; 1535-3699
• DOI: 10.1177/15353702221101810

The hexosamine biosynthetic pathway (HBP) is connected to abnormal N- and O-linked protein glycosylation in cancer, which performs critical roles in tumorigenesis. However, the regulation mechanisms of HBP and its role in colorectal cancer (CRC) progression remain unexplained. This study analyzed the expression level of phosphoglucomutase 3 (PGM3), a key enzyme in HBP, and identified its function in CRC cell lines. Analysis of publicly available CRC microarray data determined that PGM3 is upregulated in CRC tumor tissues. Furthermore, functional experiments emphasized the significant roles of PGM3 in facilitating CRC cell proliferation and migration. Mechanistically, we demonstrated that the activity of β-catenin in CRC was maintained by PGM3-mediated O-GlcNAcylation. PGM3 knockdown or inhibition of O-GlcNAc transferase decreased β-catenin activity and the expression levels of its downstream targets. Collectively, our findings indicate that PGM3 exhibits tumor-promoting roles by elevating O-GlcNAcylation level and maintaining β-catenin activity, and might serve as a prognostic biomarker and treatment target in CRC.